Fulvestrant
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $25.03 | 1 | 1 |
| 2020 | $6,000 | 2 | 1 |
| 2019 | $1.7M | 8 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 8 | 99.6% |
| Consulting Fee | $3,000 | 1 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,000 | 1 | 0.2% |
| Food and Beverage | $25.03 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE 1, RANDOMIZED, OPEN-LABEL, SINGLE-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETCS OF THREE FORMULATIONS OF FULVESTRANT FOR INJECTABLE SUSPENSION TEST COMPARED TO FASLODEX INJECTION REFERENCE FOLLOWING SINGLE DOSE INTRAMUSCU | Eagle Pharmaceuticals, Inc. | $1.7M | 0 |
Top Doctors Receiving Payments for Fulvestrant
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $1.7M | 8 |
| , M.D., M.S.C | Internal Medicine | Houston, TX | $6,000 | 2 |
| , MD | Hematology & Oncology | Great Neck, NY | $25.03 | 1 |
Manufacturing Companies
- Eagle Pharmaceuticals, Inc. $1.7M
- Dr.Reddy's Laboratories,Inc. $6,025
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 2
- Transactions 11
About Fulvestrant
Fulvestrant is a drug associated with $1.7M in payments to 2 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is Eagle Pharmaceuticals, Inc..
Payment data is available from 2019 to 2022. In 2022, $25.03 was paid across 1 transactions to 1 doctors.
The most common payment nature for Fulvestrant is "Unspecified" ($1.7M, 99.6% of total).
Fulvestrant is associated with 1 research study, including "PHASE 1, RANDOMIZED, OPEN-LABEL, SINGLE-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETCS OF THREE FORMULATIONS OF FULVESTRANT FOR INJECTABLE SUSPENSION TEST COMPARED TO FASLODEX INJECTION REFERENCE FOLLOWING SINGLE DOSE INTRAMUSCU" ($1.7M).